Advertisement

Topics

VM BioPharma begins dosing in Phase III trial of VM202 for NHU and PAD

19:00 EDT 3 Aug 2017 | Net Resources International

Korean biopharmaceutical company ViroMed’s US division VM BioPharma has begun dosing patients with VM202 in a Phase III clinical trial to treat non-healing diabetic foot ulcers (NHU) and associated peripheral artery disease (PAD).

Original Article: VM BioPharma begins dosing in Phase III trial of VM202 for NHU and PAD

NEXT ARTICLE

More From BioPortfolio on "VM BioPharma begins dosing in Phase III trial of VM202 for NHU and PAD"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...